Loading…
← CockpitCompetitor Analysis › 1763.HK China Isotope & Radiation Corp.Open in the cockpit ↗

China Isotope & Radiation Corp.1763.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Health Care›Medical Specialties
Momentum weak 20
Mkt cap
$428M
US dollars, full cap
Free float
69%
of shares outstanding
$/day
$146,893
20-day average traded
Fwd P/E
6.0×
forward earnings
ROIC−WACC
n/a
WACC 6.5%
Hurdle
n/a
no reverse DCF
Next earnings
133 days
31 Mar 2027
Close · HKDHK$10.82
1D0.0%
1W-7.9%
1M-9.7%
3M-33.6%
6M-40.9%
YTD-46.4%
1Y-50.2%
ATR %4.6%
52w lowhigh56.7% off high

What China Isotope & Radiation does

Employees: 3,578

China Isotope & Radiation at a glance

Size China Isotope & Radiation (1763.HK) is a Hong Kong Health Care company (Medical Specialties) with a market value of $428M, the 783rd largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$10.82 on 18 Nov 2026.

Performance Over six months the shares fell 40.9%, against -16.2% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue fell 5.1% over the last twelve months (peer median +4.6%); the operating margin is 13.1% (peer median 3.2%).

Valuation It trades at 6.0× forward earnings against a peer median of 17.1× (cheapest of 8).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 841763.HK 61
Six months, rebased to 100: China Isotope & Radiation against the median of its 20 peers (local-currency closes).

China Isotope & Radiation financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/aHK$7.80BHK$8.21BHK$7.33BHK$7.16B
Revenue growth—-5%+12%+2%—
Gross profitn/aHK$3.90BHK$3.99BHK$3.84BHK$4.09B
EBITDAn/aHK$1.30BHK$1.35BHK$1.06BHK$1.21B
Net incomen/aHK$355MHK$441MHK$410MHK$456M
Free cash flown/a-HK$53.9M-HK$1.00B-HK$836MHK$425M
Capital expendituren/aHK$615MHK$1.12BHK$992MHK$670M
Total debtn/aHK$3.12BHK$2.79BHK$1.94BHK$1.06B

Quarterly statements and history in the cockpit →

China Isotope & Radiation competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%+20%+40%-20%0%+20%REG1V300515SIMOBI6880263010973001109877CU6688358603987002016688133468530300289MASS6929MDXG1763.HK6-month return →1-month return →
Up and to the right = strong over both horizons. China Isotope & Radiation is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%10×20×30×REG1V300515688026688358688133692945491763.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. China Isotope & Radiation is the large dot.

China Isotope & Radiation competitors and peer comparison

How China Isotope & Radiation compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

China Isotope & Radiation against its 20 peers (data as of 18 Nov 2026)
Measure1763.HKPeer medianRank in peer set
1-month return-9.7%-9.3%10th lowest of 21
6-month return-40.9%-16.2%lowest of 21
Distance from 52-week high-56.7%-40.7%4th lowest of 21
Revenue growth (TTM)-5.1%+4.6%5th lowest of 20
Operating margin13.1%3.2%4th highest of 20
Forward P/E6.0×17.1×cheapest of 8
Net debt / EBITDA0.2×-1.3×2nd most indebted of 4

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
China Isotope & Radiation 1763.HKHong Kong$428M-41%-5%13%6.0×n/an/a
Revenio REG1V.HEFinland$428M-34%+44%10%17.1×18.5%+12.4%
Hunan Sundy Science and Technology 300515.SZChina$425M-16%+10%27%13.2×-0.1%+15.6%
Shoulder Innovations SIUnited States$432M+39%+55%-54%n/an/an/a
Mobia Medical MOBIUnited States$434M+2%+105%-145%n/an/an/a
Guangzhou Jet Bio-Filtration 688026.SSChina$436M+39%+5%11%35.7×20.6%+2.2%
Ningbo Tianyi Medical Appliance 301097.SZChina$418M-22%+46%8%n/an/an/a
Huaren Pharmaceutical 300110.SZChina$440M-16%-3%6%n/a5.8%+0.3%
Jenscare Scientific 9877.HKHong Kong$415M-32%+993%-106%n/an/an/a
Clarity Pharmaceuticals CU6.AXAustralia$444M-33%n/an/an/an/an/a
Chison Medical Technologies 688358.SSChina$406M-27%-1%19%19.8×9.6%+5.6%
Shanghai Kindly Enterprises Development 603987.SSChina$452M-12%0%10%n/a-1.0%-2.8%
Guangdong Shirongzhaoye 002016.SZChina$453M-26%-31%3%n/a21.5%-11.7%
Shanghai Titan Scientific 688133.SSChina$403M-26%+1%-6%8.4×n/an/a
PROTEINA 468530.KSSouth Korea$460M+5%-59%-1,178%n/an/an/a
Beijing Leadman Biochemistry 300289.SZChina$460M-9%+46%1%n/a36.0%-6.9%
Guanhao Biotech 300238.SZChina$397M-26%-12%3%n/an/an/a
908 Devices MASSUnited States$396M+36%+14%-33%n/a41.7%+15.9%
OrbusNeich Medical 6929.HKHong Kong$394M-15%+16%23%8.4×-17.6%+15.4%
MiMedx MDXGUnited States$464M-16%-23%-8%n/a10.9%+11.0%
Eiken Chemical 4549.TJapan$466M-20%+4%6%24.5×n/an/a

Questions

Which companies are China Isotope & Radiation's closest peers?
The cockpit's peer set: Revenio (REG1V.HE), Hunan Sundy Science and Technology (300515.SZ), Shoulder Innovations (SI), Mobia Medical (MOBI), Guangzhou Jet Bio-Filtration (688026.SS), Ningbo Tianyi Medical Appliance (301097.SZ), Huaren Pharmaceutical (300110.SZ), Jenscare Scientific (9877.HK).
Is China Isotope & Radiation expensive compared with its peers?
On forward p/e it trades at 6.0× against a peer median of 17.1×, cheapest of 8 in its peer set.
How has China Isotope & Radiation stock performed?
Over six months to 18 Nov 2026 the shares returned -40.9% against -16.2% for the median peer; over one year -50.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.